|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM193286521 |
| 003 |
DE-627 |
| 005 |
20231223194513.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.11.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0644.xml
|
| 035 |
|
|
|a (DE-627)NLM193286521
|
| 035 |
|
|
|a (NLM)19962350
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Drigo, Ilenia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Selective resistance to different glucocorticoids in severe autoimmune disorders
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.03.2010
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a 2009 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Resistance to glucocorticoids often occurs in patients with severe inflammatory disorders. Occasionally, this resistance could be overcome by switching to a different glucocorticoid, but the mechanisms of this selectivity are not clear. We studied this condition in three patients with severe inflammatory disorders, who responded satisfactorily to betamethasone, but could not be switched to equipotent doses of methylprednisolone or prednisone. While betamethasone displayed similar activity on lymphocyte proliferation in cells obtained from the three patients and controls, higher concentrations of methylprednisolone were needed to inhibit proliferation in patients' cells. In a competition study, the concentration of methylprednisolone that inhibited 50% of specific [(3)H]dexamethasone binding was increased in patients' lymphocytes. Higher Rhodamine-123 efflux was demonstrated in CD4 T cells from two patients, suggesting that an increased activity of membrane transporters could be responsible for the selective response to different glucocorticoids, even if P-glycoprotein and MRP1 expression was not increased
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a ATP Binding Cassette Transporter, Subfamily B, Member 1
|2 NLM
|
| 650 |
|
7 |
|a Formazans
|2 NLM
|
| 650 |
|
7 |
|a Glucocorticoids
|2 NLM
|
| 650 |
|
7 |
|a Multidrug Resistance-Associated Proteins
|2 NLM
|
| 650 |
|
7 |
|a Tetrazolium Salts
|2 NLM
|
| 650 |
|
7 |
|a MTT formazan
|2 NLM
|
| 650 |
|
7 |
|a 23305-68-2
|2 NLM
|
| 650 |
|
7 |
|a DNA
|2 NLM
|
| 650 |
|
7 |
|a 9007-49-2
|2 NLM
|
| 650 |
|
7 |
|a Betamethasone
|2 NLM
|
| 650 |
|
7 |
|a 9842X06Q6M
|2 NLM
|
| 650 |
|
7 |
|a Prednisolone
|2 NLM
|
| 650 |
|
7 |
|a 9PHQ9Y1OLM
|2 NLM
|
| 650 |
|
7 |
|a Methylprednisolone
|2 NLM
|
| 650 |
|
7 |
|a X4W7ZR7023
|2 NLM
|
| 650 |
|
7 |
|a multidrug resistance-associated protein 1
|2 NLM
|
| 650 |
|
7 |
|a Y49M64GZ4Q
|2 NLM
|
| 700 |
1 |
|
|a Piscianz, Elisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Valencic, Erica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a De Iudicibus, Sara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tommasini, Alberto
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ventura, Alessandro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Decorti, Giuliana
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 134(2010), 3 vom: 18. März, Seite 313-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:134
|g year:2010
|g number:3
|g day:18
|g month:03
|g pages:313-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.11.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 134
|j 2010
|e 3
|b 18
|c 03
|h 313-9
|